Cesca Therapeutics (NASDAQ: MSON) and Misonix (NASDAQ:MSON) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.
This table compares Cesca Therapeutics and Misonix’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Cesca Therapeutics has a beta of -0.96, suggesting that its stock price is 196% less volatile than the S&P 500. Comparatively, Misonix has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500.
This is a summary of recent ratings and target prices for Cesca Therapeutics and Misonix, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cesca Therapeutics currently has a consensus price target of $1.50, suggesting a potential upside of 252.11%. Misonix has a consensus price target of $26.00, suggesting a potential upside of 41.69%. Given Cesca Therapeutics’ higher possible upside, equities research analysts clearly believe Cesca Therapeutics is more favorable than Misonix.
Institutional and Insider Ownership
3.3% of Cesca Therapeutics shares are held by institutional investors. Comparatively, 13.0% of Misonix shares are held by institutional investors. 15.7% of Cesca Therapeutics shares are held by company insiders. Comparatively, 24.6% of Misonix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Cesca Therapeutics and Misonix’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cesca Therapeutics||$14.52 million||0.61||-$20.24 million||($0.98)||-0.43|
|Misonix||$36.68 million||4.70||-$7.61 million||N/A||N/A|
Misonix has higher revenue and earnings than Cesca Therapeutics.
Misonix beats Cesca Therapeutics on 10 of the 11 factors compared between the two stocks.
Cesca Therapeutics Company Profile
Cesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. It offers AutoXpress System, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood; Point-of-CareXpress System, a proprietary automated device and companion sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow; CAR-TXpress System, a suite of multi-component automated system that allows the automated manufacturing, expansion, and storage of cellular therapies for immuno-oncology; BioArchive System, an automated cryogenic device for single-cassette based cryo-storage of biological license applications products; and manual bag sets for use in the processing and cryogenic storage of cord blood. The company is also developing autologous stem cell-based therapies that address medical needs for applications in the vascular, cardiology, and orthopedic markets. In addition, it provides cell manufacturing and banking services. The company was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California. Cesca Therapeutics Inc. is a subsidiary of Boyalife (Hong Kong) Limited.
Misonix Company Profile
Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells, as well as other medical devices. Its products are used in various clinical specialties, such as neurosurgery, orthopedic surgery, plastic surgery, wounds, and maxillo-facial applications. The company sells its products through sales representatives and distributors. Misonix, Inc. was founded in 1959 and is based in Farmingdale, New York.
Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.